

1 FW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John M. Williams
Application No.: 10/719,701 Group Art Unit: 1646
Filed: November 21, 2003 Examiner: Not Assigned
Confirmation No.: 1350
Title: Induction of Immune Tolerance

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
7/8/04 Date	<i>Carol M. Bowerman</i> Signature
Carol M. Bowerman Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:
☐ a Statement under 37 CFR 1.97(e), as checked below, or
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:
☐ a Statement under 37 CFR 1.97(e), as checked below, and
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)
Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references are enclosed.
- ☒ Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
- ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☒ The listed references, AL, AM, AN, AS and AT, were cited in the enclosed International Search Reports in counterpart foreign applications.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

☒ Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. 10/719,055, by John M. Williams, filed November 21, 2003,
Docket No.: 2478.2018-001

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

- ☒ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:


- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Kraig K. Anderson
Kraig K. Anderson
Registration No.: 54,961
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133
Dated: July 8, 2004

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2478.2017-001		APPLICATION NO. 10/719,701	
 <p>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>July 2, 2004</p> <p>Use several sheets if necessary)</p>		FIRST NAMED INVENTOR John M. Williams		FILING DATE November 21, 2003	
		EXAMINER Not Assigned		CONFIRMATION NO. 1350	

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	5,540,931	07-30-1996	Hewitt, <i>et al.</i>
	AB	5,654,312	08-05-1997	Andrulis, Jr., <i>et al.</i>
	AG	5,795,967	08-18-1998	Aggarwal, <i>et al.</i>
	AD	5,801,193	09-01-1998	Ojo-Amaize, <i>et al.</i>
	AE	5,958,413	09-28-1999	Anagnostopoulos, <i>et al.</i>
	AI	5,990,103	11-23-1999	Schonharting, <i>et al.</i>
	AG	6,020,323	02-01-2000	Cohen, <i>et al.</i>
	AH	6,030,615	02-29-2000	Bucala, <i>et al.</i>
	AI	6,204,245	03-20-2001	Siegel, <i>et al.</i>
	AJ	6,211,160	04-03-2001	Wilson, <i>et al.</i>
	AI	6,235,281	05-22-2001	Stenzel, <i>et al.</i>
	AA2	6,299,873	03-20-2001	Boone, <i>et al.</i>
	AB2	6,270,766 B1	08-07-2001	Feldman, <i>et al.</i>
	AG2	6,299,878	10-09-2001	Pierpadi, <i>et al.</i>
	AD2	6,306,820 B1	10-23-2001	Bendele, <i>et al.</i>
	AE2	6,331,560	12-18-2001	Shohami, <i>et al.</i>
	AF2	6,337,325	01-08-2002	Schonharting, <i>et al.</i>
	AG2	6,376,665	04-23-2002	Duan, <i>et al.</i>
	AH2	6,420,374 B1	07-16-2002	Bianco, <i>et al.</i>
	AI2	6,432,962	08-13-2002	Horneman
	AJ2	6,432,968 B1	08-13-2002	Schonharting, <i>et al.</i>
	AK2	6,503,184	01-07-2003	Ni, <i>et al.</i>
	AA3	6,506,569 B1	01-14-2003	Ni, <i>et al.</i>
	AB3	6,509,015 B1	01-21-2003	Salfeld, <i>et al.</i>
	AC3	2002/0119988 A1	08-29-2002	Sneddon, <i>et al.</i>

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.

APPLICATION NO.

2478.2017-001

10/719,701

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

FIRST NAMED INVENTOR

FILING DATE

John M. Williams

November 21, 2003

EXAMINER

CONFIRMATION NO.

GROUP

Not Assigned

1350

1646

Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	AL	WO 01/87849	11-22-2001	Genzyme Corporation		
	AM	WO 98/39026	09-11-1998	Biogen Inc.		
	AN	EP 0 401 747 A	12-12-1990	Calne		
	AO	WO 95/09652	04-13-1995	The Kennedy Institute for Rheumatology		
	AP	WO 94/08619	04-28-1994	The Kennedy Institute for Rheumatology		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Yuan, X. <i>et al.</i> , "A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection," <i>Transplantation</i> 73(11):1736-1742 (2002).
	AS	Turner, D. M., <i>et al.</i> , "A Genetic Marker of High TNF- α Production in Heart Transplant Recipients," <i>Transplantation</i> , 60(10):1113-1117 (1995).
	AT	Couriel, D., <i>et al.</i> , "TNF-Alpha Inhibition for the Treatment of Chronic GVHD," <i>Blood</i> , 100(11):847a (2002) Abstract.
	AU	Hancock, W. W., <i>et al.</i> , "Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection," <i>Proc. Natl. Acad. Sci. USA</i> 93:13967-13972 (1996).

EXAMINER

DATE CONSIDERED